A Multicenter Phase III Uncontrolled Open-label Trial to Evaluate Safety and Efficacy of BAY81-8973 in Children With Severe Hemophilia A Under Prophylaxis Therapy
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms LEOPOLD Kids
- Sponsors Bayer
- 15 Sep 2017 Planned End Date changed from 29 Dec 2019 to 31 Dec 2022.
- 15 Sep 2017 Planned primary completion date changed from 29 Dec 2019 to 31 Dec 2022.
- 27 Jul 2017 This trial has been completed in Latvia.